EUVIMEDEUVIMED entdecken
Korrektur

Correction to: Osimertinib-induced erythema dyschromicum perstans

Clinical and Experimental Dermatology · 17.08.2026 · 51 (9) · 1801-1801

DOI: 10.1093/ced/llag239 ↗

Kurz gefasst

Korrektur in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 12.06.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Correction to: Osimertinib-induced erythema dyschromicum perstans. Clinical and Experimental Dermatology, 51(9), 1801-1801. https://doi.org/10.1093/ced/llag239

Vancouver

Correction to: Osimertinib-induced erythema dyschromicum perstans. Clinical and Experimental Dermatology. 2026;51(9):1801-1801. doi:10.1093/ced/llag239

BibTeX
@article{euvimed2026,
  title = {Correction to: Osimertinib-induced erythema dyschromicum perstans},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  volume = {51},
  number = {9},
  pages = {1801--1801},
  doi = {10.1093/ced/llag239}
}
Kostenlos starten →